<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524173</url>
  </required_header>
  <id_info>
    <org_study_id>070207</org_study_id>
    <secondary_id>07-DK-0207</secondary_id>
    <nct_id>NCT00524173</nct_id>
  </id_info>
  <brief_title>Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B</brief_title>
  <official_title>Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether the combination of two medications, tenofovir and emtricitabine,
      are safer and more effective for treating chronic hepatitis B than tenofovir alone. Chronic
      hepatitis B is a liver disease caused by infection with the hepatitis B virus. Several
      medications, including standard and pegylated interferon and the anti-viral drugs lamivudine,
      adefovir, entecavir and telbivudine, are currently used to treat the disease. Problems are
      associated with all of these agents, however, including development of viral resistance with
      long-term therapy of the anti-virals. Since many patients require long-term therapy to
      prevent their disease from worsening, a major goal of new approaches to treatment is to
      prevent the development of viral resistance. Combination treatment has been shown to be an
      effective strategy in preventing this resistance.

      Tenofovir is an anti-viral drug approved for use in patients with HIV infection. In small
      studies in patients infected with both HIV and hepatitis B, tenofovir lowered the level of
      hepatitis B virus in the blood, with no viral resistance reported when used for up to 5
      years. Emtricitabine is an anti-viral drug similar to lamivudine and is effective at lowering
      viral load and improving liver damage.

      Patients 18 years of age and older with chronic hepatitis B may be eligible for this study.
      Participants are admitted to the NIH Clinical Center for a complete medical history and
      examination, including blood and urine tests, chest X-ray, electrocardiogram, abdominal
      ultrasound, Fibroscan (ultrasound exam of the liver that measures the amount of scarring),
      bone mineral density scan and liver biopsy. They are then randomly assigned to take
      combination treatment with tenofovir plus emtricitabine or tenofovir alone for at least 48
      weeks. During the treatment period, patients visit the Clinical Center for blood tests and a
      physical examination every 2 weeks for the first month and then every 4 to 12 weeks. After 48
      weeks, patients are readmitted to the Clinical Center for a complete evaluation that includes
      all the tests done at the start of therapy, including a liver biopsy. Patients who seem to
      have improved with treatment may continue therapy for up to 192 weeks, when they are again
      admitted to the Clinical Center for a complete medical evaluation and liver biopsy. Patients
      whose condition has not improved after 48 weeks of treatment have their treatment changed or
      stopped and continue to have regular outpatient clinic visits for 24 more weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B is a major cause of cirrhosis, end-stage liver disease and hepatocellular
      carcinoma and affects approximately 1.25 million Americans. Six medications have been
      licensed for use in chronic hepatitis B in the United States, but their relative benefit and
      long-term efficacy remain unclear. In previous studies, we have shown that maintained
      suppression of HBV DNA can be achieved with nucleoside analogues and that suppression is
      associated with marked improvements in disease. In this randomized study, we propose to
      evaluate long-term therapy with tenofovir alone or in combination with emtricitabine (FTC).
      Forty treatment-naive patients with chronic hepatitis B will be enrolled in the primary
      study. After medical evaluation and liver biopsy, patients will be stratified by hepatitis B
      e antigen (HBeAg) status and randomized to receive either tenofovir alone or in combination
      with FTC. Treatment will be continued long-term (at least four years) and patients will be
      carefully monitored for side effects, serum aminotransferase and HBV DNA levels. Patients
      will undergo repeat liver biopsy and assessment of antiviral resistance at 1 and 4 years. The
      primary endpoint of therapy will be the maintained suppression of HBV DNA to below 10(2)
      copies/ml (lower limit of detection of current assays). The study will assess the relative
      efficacy and safety of combination versus mono-therapy. A separate group of 60 previously
      treated patients will also be enrolled and randomized to mono- or combination-therapy to
      assess the safety profile of these agents. The primary analysis will be conducted on the
      entire study cohort.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 29, 2007</start_date>
  <completion_date type="Actual">February 16, 2017</completion_date>
  <primary_completion_date type="Actual">February 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With HBV DNA &lt;1000 IU/ml at Week 48</measure>
    <time_frame>At Week 48</time_frame>
    <description>Number of subjects with HBV DNA &lt;1000 IU/ml at Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With HBV DNA &lt;1000 IU/ml at Week 192</measure>
    <time_frame>At Week 192</time_frame>
    <description>Number of participants with HBV DNA &lt;1000 IU/ml at Week 192</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Normalized ALT</measure>
    <time_frame>192 weeks</time_frame>
    <description>Number of participants with normalized ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of HBsAg</measure>
    <time_frame>192 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tenofovir only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg by mouth daily for 192 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir &amp; emtricitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir &amp; Emtricitabine</intervention_name>
    <arm_group_label>Tenofovir &amp; emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <arm_group_label>Tenofovir only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA (nucleoside analogue-naive subjects):

          -  Age greater than 18 years and older, male or female.

          -  Known serum HBsAg positivity for 24 weeks.

          -  Detectable HBV DNA greater than 10(4) IU/ml. For patients with cirrhosis HBV DNA
             greater than 10(3) IU/ml

          -  Serum ALT or AST levels 1.5 times the upper limit of normal (for ALT: greater than or
             equal to 62 U/L and for AST greater than or equal to 46 U/L) based on at least two
             determinations taken at least one month apart during the 24 weeks before study entry;
             no ALT requirement for patients with cirrhosis.

          -  Liver biopsy within 2 years of entry that is consistent with chronic hepatitis and
             with a histology activity index (HAI) score of 4 or more (scores range from 0-18) and
             an Ishak fibrosis score of at least 1 (scores range from 0-6). For patients who have
             had a liver biopsy at another institution, slides must be obtained for reading and
             scoring at the NIH.

          -  Written informed consent.

        INCLUSION CRITERIA SALVAGE STUDY (nucleoside analogue experienced subjects):

          -  Age &gt;18 years and older, male or female

          -  Known serum HBsAg positivity for 6 months

          -  Detectable HBV DNA &gt;10(2) IU/ml.

          -  Liver biopsy within 5 years of entry that is consistent with chronic hepatitis

          -  Written informed consent

        INCLUSION CRITERIA: SALVAGE STUDY (relapsers)

          -  Age greater than 18 years and older, male or female.

          -  Known serum HBsAg positivity for 6 months.

          -  Detectable HBV DNA greater than 10(3) IU per milliliter.

          -  Liver biopsy within 5 years of entry that is consistent with chronic hepatitis.

          -  Written informed consent.

        Serum ALT or AST levels 1.5 times the ULN (for ALT: greater than 62 U/L and for AST:
        greater than 46 U/L) based on at least two determinations taken at least 2 weeks apart.

        EXCLUSION CRITERIA:

          -  Previous or current treatment with tenofovir or emtricitabine.

          -  Co-infection with HDV as defined by the presence of anti-HDV in serum and/or HDV
             antigen in the liver.

          -  Co-infection with HCV as defined by the presence of HCV RNA in serum.

          -  Co-infection with HIV as defined by the presence of anti-HIV in serum.

          -  Decompensated liver disease as defined by serum bilirubin greater than 2.5 milligram
             per deciliter (with direct bilirubin greater than 0.5 milligram per deciliter),
             prothrombin time of greater than 2 seconds prolonged, a serum albumin of less than 3
             grams per deciliter, or a history of ascites, variceal bleeding or hepatic
             encephalopathy.

          -  Presence of other causes of liver disease (i.e. hemochromatosis, Wilson disease,
             alcoholic liver disease, nonalcoholic steatohepatitis, alpha-1anti-trypsin
             deficiency).

          -  A history of organ transplantation or in the absence of organ transplantation, any
             immunosuppressive therapy requiring the use of more than 5 milligrams of prednisone
             (or its equivalent) daily.

          -  Significant systemic illness other than liver diseases including congestive heart
             failure, renal failure, chronic pancreatitis, diabetes mellitus with poor control that
             in the opinion of the investigator may interfere with therapy.

          -  Pregnancy or inability to practice contraception in patients capable of bearing or
             fathering children and lactating women.

          -  Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the
             liver that is suggest of HCc, or an alpha-fetoprotein level of greater than 500ng/mL.

          -  History of clinically apparent pancreatitis or evidence of subclinical pancreatitis as
             shown by serum amylase values twice the upper limits of the normal range and
             abnormalities of the pancreas on CT or other imaging studies of the abdomen.

          -  Sensory or motor neuropathy apparent from medical history and physical examination.

          -  Creatinine clearance less than 50 ml/min, serum creatinine greater than 1.3 mg/dl or
             urine protein greater than 1 gram/24 hours; creatinine clearance will be determined on
             the average of two 24 hour urine specimens. Accuracy of collection will be ensured by
             documenting appropriate total creatinine excretion in the 24 hour urine specimen
             (15mg/kg) and correcting for the patient's age, gender and body surface area.

          -  Concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B,
             vancomycin, foscarnet, cis-platinum, pentamidine, nonsteroidal anti-inflammatory
             agents) or competitors of renal tubular excretion (e.g. probenecid) within 2 months
             prior to study screening or the expectation that the subject will receive these during
             the course of the study.

          -  History of hypersensitivity to nucleoside analogues.

          -  Active ethanol/drug abuse/psychiatric problems such as major depression,
             schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety,
             personality disorder that, in the investigator's opinion, might interfere with
             participation in the study.

          -  History of renal tubular acidosis.

          -  History of malignancy or treatment for a malignancy within the past 5 years.

          -  Presence of conditions that, in the opinion of the investigators, would not allow the
             patient to be followed in the current study for at least 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc G Ghany, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1011-20. Erratum in: N Engl J Med. 2006 Apr 27;354(17):1863.</citation>
    <PMID>16525138</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800-7. Erratum in: N Engl J Med. 2003 Mar 20;348(12):1192.</citation>
    <PMID>12606734</PMID>
  </reference>
  <reference>
    <citation>Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999 Oct 21;341(17):1256-63.</citation>
    <PMID>10528035</PMID>
  </reference>
  <verification_date>March 16, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>March 20, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2018</results_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emtricitabine</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Antiviral Therapy</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir Only</title>
          <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
        </group>
        <group group_id="P2">
          <title>Tenofovir &amp; Emtricitabine</title>
          <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Had not reached endpoint at study close</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir Only</title>
          <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
        </group>
        <group group_id="B2">
          <title>Tenofovir &amp; Emtricitabine</title>
          <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.65" spread="16.66"/>
                    <measurement group_id="B2" value="39.47" spread="12.67"/>
                    <measurement group_id="B3" value="39.56" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With HBV DNA &lt;1000 IU/ml at Week 48</title>
        <description>Number of subjects with HBV DNA &lt;1000 IU/ml at Week 48</description>
        <time_frame>At Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Only</title>
            <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir &amp; Emtricitabine</title>
            <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With HBV DNA &lt;1000 IU/ml at Week 48</title>
          <description>Number of subjects with HBV DNA &lt;1000 IU/ml at Week 48</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With HBV DNA &lt;1000 IU/ml at Week 192</title>
        <description>Number of participants with HBV DNA &lt;1000 IU/ml at Week 192</description>
        <time_frame>At Week 192</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Only</title>
            <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir &amp; Emtricitabine</title>
            <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBV DNA &lt;1000 IU/ml at Week 192</title>
          <description>Number of participants with HBV DNA &lt;1000 IU/ml at Week 192</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Normalized ALT</title>
        <description>Number of participants with normalized ALT</description>
        <time_frame>192 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Only</title>
            <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir &amp; Emtricitabine</title>
            <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Normalized ALT</title>
          <description>Number of participants with normalized ALT</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Loss of HBsAg</title>
        <time_frame>192 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Only</title>
            <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir &amp; Emtricitabine</title>
            <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Loss of HBsAg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>192 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir Only</title>
          <description>Tenofovir 300mg by mouth daily for 192 weeks
Tenofovir</description>
        </group>
        <group group_id="E2">
          <title>Tenofovir &amp; Emtricitabine</title>
          <description>Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
Tenofovir &amp; Emtricitabine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils (&lt;750mm^3)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Serum amylase &gt;2xULN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Aalanine aminotransferase &gt;5xULN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase &gt; 5xULN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Creatine kinase &gt; 4xULN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Ghany, MD</name_or_title>
      <organization>NIDDK</organization>
      <phone>301-402-5115</phone>
      <email>marcg@intra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

